Century Therapeutics News

Century Therapeutics Presents Interim Results From Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting

In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting Encouraging preliminary efficacy in heavily

GlobeNewswire07:00 ET

Century Therapeutics(IPSC.US) Officer Sells US$14,977.5 in Common Stock

$Century Therapeutics(IPSC.US)$ Officer Russotti Gregory sold 5,000 shares of common stock on May 20, 2024 at an average price of $2.9955 for a total value of $14,977.5.Source: Announcement What is st

moomoo NewsMay 21 16:52 ET

Buy Rating Affirmed for Century Therapeutics on Promising CNTY-101 Prospects and Strong Financial Footing

TipRanksMay 16 04:13 ET

Express News | Century Therapeutics Inc Files for Shelf of up to 15.9 Mln Shares of Common Stock by Selling Stockholders - SEC Filing

ReutersMay 15 16:10 ET

Express News | Century Therapeutics Inc : Guggenheim Cuts Target Price to $12 From $14

ReutersMay 14 06:15 ET

Century Therapeutics Inc (IPSC) Q1 2024 Earnings: Aligns With EPS Projections Amid Strategic ...

Yahoo FinanceMay 10 15:35 ET

Century Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Century Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 10 07:55 ET

Express News | Century Therapeutics Presents Preclinical Data Highlighting Advances In IPSC Platform Technology And Programs At 2024 ASGCT Annual Meeting

BenzingaMay 10 07:23 ET

Century Therapeutics Presents Preclinical Data Highlighting Advances in IPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting

In vitro data showcases CNTY-101's ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases including systemic lupus erythematosus (SLE)Preclinical data demonstrates

GlobeNewswireMay 10 07:00 ET

Century Therapeutics: A Promising Buy Amidst Clinical and Strategic Advances

TipRanksMay 10 06:47 ET

Express News | Century Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $11 From $13

ReutersMay 10 06:34 ET

Century Therapeutics: A Hold Rating Amid Anticipated Clinical Data and Strategic Expansion

TipRanksMay 9 15:06 ET

Century Therapeutics Q1 2024 GAAP EPS $(0.45) Beats $(0.52) Estimate, Sales $855.000K Miss $1.262M Estimate

Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.52) by 13.46 percent. This is a 15.09 percent increase over losses of

BenzingaMay 9 07:58 ET

Century Therapeutics 1Q Loss $28.1M >IPSC

Century Therapeutics 1Q Loss $28.1M >IPSC

Dow JonesMay 9 07:35 ET

Century Therapeutics | 10-Q: Quarterly report

SEC announcementMay 9 07:32 ET · Announcements

Express News | Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

ReutersMay 9 07:30 ET

Express News | Century Therapeutics Outlook FY Operating Expenses USD 150-160 Million

ReutersMay 9 07:30 ET

Century Therapeutics(IPSC.US) Officer Sells US$15,619 in Common Stock

$Century Therapeutics(IPSC.US)$ Officer Russotti Gregory sold 5,000 shares of common stock on May 6, 2024 at an average price of $3.1238 for a total value of $15,619.Source: Announcement What is state

moomoo NewsMay 7 17:55 ET

Century Therapeutics(IPSC.US) Officer Sells US$15,489.5 in Common Stock

$Century Therapeutics(IPSC.US)$ Officer Russotti Gregory sold 5,000 shares of common stock on Apr 22, 2024 at an average price of $3.0979 for a total value of $15,489.5.Source: Announcement What is st

moomoo NewsApr 24 17:00 ET

Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

PHILADELPHIA, April 23, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and

GlobeNewswireApr 23 07:00 ET